Trials and PIs

 
 
  • CLEVER with Dr Emile Mohler   Penn Heart and Vascular Center(Penn Heart and Vascular Center , Philadelphia) discusses six–month outcomes from the CLEVER study on claudication treatment comparative effectiveness with Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC). Filme
  • TRA-CER with Dr Kenneth Mahaffey   Dr Kenneth Mahaffey (Duke Clinical Research Institute, Durham, NC) discusses the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA–CER) trial with Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC).
  • Lipid-modulating effects of evacetrapib Dr Stephen Nicholls   Stephen Nicholls (Cleveland Clinic, Cleveland, OH) on the lipid-modulating effects of evacetrapib administered as monotherapy or in combination with the most commonly used statins with Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC). Filmed
  • SATURN with Dr Stephen Nicholls   Stephen Nicholls (Cleveland Clinic, Cleveland, OH) talks about the progression of coronary atherosclerosis for two high-efficacy statin regimens with different HDL effects with Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC). Filmed at AHA
  • ISAR-REACT 4 with Dr Adnan Kastrati   Dr Adnan Kastrati (Deutsches Herzzentrum, Munich, Germany) discusses abciximab plus unfractionated heparin vs bivalirudin in patients with non–ST–segment-elevation MI undergoing percutaneous coronary intervention. The ISAR–REACT 4 randomized trial with Dr
  • Dr John Spertus on individualized informed-consent form to improve patients' experiences with PCI   Dr John Spertus (Mid America Heart Institute, Kansas City, MO) discusses evidence–based, individualized informed-consent form to improve patients' experiences with PCI with Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC). Filmed at AHA 2011
  • AIM-HIGH with Dr William Boden   Dr William Boden (University of Buffalo, NY) discusses results from the AIM–HIGH trial and how extended-release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL cholesterol is optimally controlled with s
  • ALPHEE with Dr Peter Kowey   Dr Peter Kowey (MLH Heart Center Lankenau Medical Center, Wynnewood, PA) discusses the double-blind placebo-controlled dose-ranging study of the efficacy and safety of celivarone 50, 100, or 300 mg daily with amiodarone as calibrator for the prevention of
  • Dr Richard Lowrie on pharmacist intervention to prevent hospitalization and death in patients with heart failure   Dr Richard Lowrie (National Health Service, Greater Glasgow and Clyde, Glasgow, Scotland) discusses pharmacist intervention to prevent hospitalization and death in patients with heart failure, a prospective cluster randomized controlled trial, with Dr Man
  • Post-MI FREEE with Dr Niteesh Choudry   Dr Niteesh Choudhry (Harvard Medical School, Boston, MA) discusses the Post–MI FREEE trial and the impact of full coverage for preventive medications after MI on recurrent vascular events with Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC)
  • Dr Jens Cosedis Nielsen on the comparison of radiofrequency ablation and antiarrhythmic drug therapy as first-line treatment in paroxysmal atrial fibrillation   Dr Jens Cosedis Nielsen (Aarhus University Hospital, Skejby, Aarhus N, Denmark) discusses the randomized multicenter comparison of radiofrequency ablation and antiarrhythmic drug therapy as first-line treatment in 294 patients with paroxysmal AF with Dr M
  • PALLAS with Dr Stuart Connolly   Dr Stuart Connolly (McMaster University, Hamilton, ON) discusses the results of the PALLAS study with Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC). Filmed at AHA 2011.
  • CRISP-AMI with Dr Manesh Patel   Dr Manesh Patel (Duke Clinical Research Institute, Durham, NC) discusses the multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size pre-PCI for acute MI: Rationale and design with Dr
  • Dr Lorenz Räber on newer-generation everolimus-eluting stents eliminating the risk of very late stent thrombosis compared with early-generation sirolimus-eluting and paclitaxel-eluting stents   Dr Lorenz Räber (Berne University Hospital, Switzerland) discusses his hot-line presentation with Dr Robert Byrne (German Heart Center, Munich).Filmed during ESC 2011 in Paris on August 28.
  • PRODIGY with Dr Marco Valgimigli   Dr Marco Valgimigli (Azienda Ospedaliero-Universitaria Sant'Anna, Ferrara, Italy) discusses the randomized comparison of six vs 24 months of clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing PCI wi
  • HCS with Dr Ulrich Laufs   Dr Ulrich Laufs (Universitätskliniken des Saarlandes, Homburg/Saar, Germany) discusses the prospective evaluation of postprandial triglycerides and cardiovascular events in patients with coronary artery disease with Dr Robert Byrne (German Heart Center, M
  • RESET with Dr Takeshi Kimura   Dr Takeshi Kimura (Otowa Hospital, Kyoto, Japan) discusses the randomized evaluation of the sirolimus-eluting vs everolimus-eluting stent trial with Dr Robert Byrne (German Heart Center, Munich).Filmed during ESC 2011 in Paris, France on August 29.
  • ARISTOTLE with Dr Christopher Granger   Dr Christopher Granger (Duke University, Durham, NC) discusses the efficacy and safety of apixaban compared with warfarin for prevention of stroke and systemic embolism in 18 202 patients with atrial fibrillation: Primary results with Dr Robert Byrne.
  • Dr Hiroki Shiomi on the comparison of three-year outcomes after PCI and CABG stratified by the SYNTAX score in patients with triple-vessel coronary artery disease: An observation from the CREDO-Kyoto PCI/CABG registry cohort-2   Dr Hiroki Shiomi (Kyoto University, Japan) discusses his hot-line presentation with Dr Robert Byrne (German Heart Center, Munich).Filmed during ESC 2011 in Paris on August 28.
  • EMPHASIS-HF with Dr Bertram Pitt   Dr Bertram Pitt (University of Michigan, Ann Arbor) discusses the effect of eplerenone vs placebo on cardiovascular mortality or heart-failure hospitalization in subjects with NYHA class 2 chronic systolic heart failure: An analysis of the high-risk group
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.